- Investing Ideas
- South Korean Pharmaceuticals & Biotech Undervalued based on future growth
South Korean Pharmaceuticals & Biotech Undervalued based on future growth
Results
3
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
3 companies
Seegene
Market Cap: ₩1.1t
Manufactures and sells molecular diagnostics products worldwide.
A096530
₩23,900.00
7D
6.9%
1Y
1.5%
Daihan PharmaceuticalLtd
Market Cap: ₩168.2b
Engages in the manufacture and sale of therapeutic drugs in South Korea.
A023910
₩28,600.00
7D
-0.2%
1Y
12.4%
DreamCIS
Market Cap: ₩115.9b
Operates as a clinical research organization in South Korea.
A223250
₩4,715.00
7D
-0.4%
1Y
66.3%